Clinical Research

Clinical Trials

Clinical trials are investigations where patients willingly participate to contribute to the discovery of answers to health inquiries. When conducted with caution, they represent the most secure and efficient method of uncovering novel treatments and enhancing overall well-being. The advancement of medicine would not be possible without the continued participation of patients in clinical research.

Samaritan’s clinical research program was established in 2008. Sponsors have included: Pfizer, Boehringer Ingelheim, Spectrum, Celgene, Genentech, Amgen, Genentech, Tragara, Bracco Diagnostic, Eisai, PUMA, Novartis, Incyte, Pharmatech, Medtronic, St. Jude Medical and the National Institutes of Health.

  • National Institute of Health and Federal Drug Administration registration number: IRB00005278.
  • Institutional Organization Number (IORG) is IORG0004448.
  • We are a research affiliate of UCSF for The Alliance for Clinical Trials in Oncology.

For more information, email [email protected] or call 541-768-4352.

Current Studies

TitleMore Information
Blood Purification for the Treatment of Pathogen Associated Shock (PURIFY-RCT)
Principal Investigator: Brian Delmonaco, MD
For more information on this trial.
Assessment of Implementation Methods in Sepsis and Respiratory Failure (AIMS)
Principal Investigator: Brian Delmonaco, MD
Email [email protected].
COVID-19 Specimen Biobank
Principal Investigator: Adam Brady, MD
Email [email protected].

Breast

TitleMore Information
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
Principal Investigator: Rachel Shirley, DO
For more information on this trial.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Principal Investigator: Robert Davis, MD
For more information on this trial.

Lung

TitleMore Information
Lung Cancer Screening Program
Principal Investigator: Vanessa Mizak, NP, and Brian Delmonaco, MD
Email: [email protected].
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Principal Investigator: John Strother, MD
For more information on this trial.
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
Principal Investigator: John Strother, MD
For more information on this trial.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Principal Investigator: John Strother, MD
For more information on this trial.
Lung Cancer Companion Diagnostic
 Principal Investigator: Tomer Pelleg, DO
Email [email protected].


Other

TitleMore Information
Multiple Metastatic Tumors
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas or Multiple Myeloma
(The MATCH Screening Trial)
Principal Investigator: John Strother, MD
For more information on this trial.
Sarcoma
Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds

Principal Investigator: Nicholas Tedesco, DO
For more information on this trial.
Orthopedic Tumor Surgery
Orthopedic Tumor Data Registry

Principal Investigator: Nicholas Tedesco, DO
Email: [email protected].
realMIND: Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second- or Third-line Therapy (realMIND)
Principal Investigator: Robert Davis, MD
For more information on this trial.
Metastatic Bone Reconstructions
Principal Investigator: Nicholas Tedesco, DO
Email: [email protected]
Multiple Solid Tumor Cancer Detection  
Principal Investigator: John Strother, MD
Email: [email protected].
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Principal Investigator: John Strother, MD
For more information on this trial.

TitleMore Information
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)
Principal Investigator: Jeremy Warner, DO
For more information on this trial.

TitleMore Information
A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)
Principal Investigator: Jonathan Jones, MD
For more information on this trial.
Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
Principal Investigator: Jonathan Jones, MD
For more information on this trial.
Rheumatology Biorepository
Principal Investigator: Jonathan Jones, MD
For more information on this trial.
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Principal Investigator: Jonathan Jones, MD
For more information on this trial.

TitleMore Information
Benign Soft Tissue Tumor Resection
Principal Investigators: Jared Sanderford, DO, and Nicholas Tedesco, DO
Email: [email protected].
Use of Empagliflozin to Treat Prediabetes – a Randomized, Double-blind, Placebo-controlled 13-week Intervention Trial
Principal Investigators: Sean Newsom, PhD, and Matthew Robinson, Ph.D. (Oregon State University)
For more information on this trial.
A survey study on the effects of Purewick external catheterizing during hospitalization on urinary incontinence in adults. 
Principal Investigators: Breanne Myers, PT, DPT, and Stacy Mosbrucker, PTA, BS
Email: [email protected].
Responses to Life Stresses Survey
Principal Investigator: Thomas Field, Ph.D. (Oregon State University)
Email: [email protected].

For more information about clinical research at Samaritan, contact us at 541-768-4352 or [email protected].

circle-chevronemailfacebookSHS AffiliateinstagramlinkedinMyChart IconMyHealthPlan IconphonepinterestSearch Iconsilhouettetwitteryoutube